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Syncytin-1 has a physiological role during early pregnancy, as mediator of trophoblast fusion into the syncytiotrophoblast layer, hence
allowing embryo implantation. In addition, its expression in nerve tissue has been proposed to contribute to the pathogenesis of multiple sclerosis
(MS). Syncytin-1 is the env glycoprotein of the ERVWE1 component of the W family of human endogenous retroviruses (HERV), located on
chromosome 7q21–22, in a candidate region for genetic susceptibility to MS. The mechanisms of ERVWE1 regulation in nerve tissue remain to
be identified. Since there are correlations between some cytokines and MS outcome, we examined the regulation of the syncytin-1 promoter by
MS-related cytokines in human U-87MG astrocytic cells. Using transient transfection assays, we observed that the MS-detrimental cytokines
TNFα, interferon-γ, interleukin-6, and interleukin-1 activate the ERVWE1 promoter, while the MS-protective interferon-β is inhibitory. The
effects of cytokines are reduced by the deletion of the cellular enhancer domain of the promoter that contains binding sites for several transcription
factors. In particular, we found that TNFα had the ability to activate the ERVWE1 promoter through an NF-κB-responsive element located within
the enhancer domain of the promoter. Electrophoretic mobility shift and ChIP assays showed that TNFα enhances the binding of the p65 subunit
of NF-κB, to its cognate site within the promoter. The effect of TNFα is abolished by siRNA directed against p65. Taken together, these results
illustrate a role for p65 in regulating the ERVWE1 promoter and in TNFα-mediated induction of syncytin-1 in multiple sclerosis.
© 2007 Elsevier Inc. All rights reserved.Keywords: Syncytin promoter; Cytokines; Multiple sclerosis; U-87MGIntroduction
Human endogenous retrovirus (HERV) elements form at
least 8% of the human genome, and are remnants of past
retroviral infections during evolution. In general, they are
highly defective, but a few cases of complete proviruses have
also been described (Dolei, 2006) as well as some incomplete
forms that have retained coding capacity. Two components of
the HERV-W family, multiple sclerosis-associated retrovirus
(MSRV) and syncytin-1, have been implicated in some
pathological and physiological phenomena (Dolei, 2006;
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doi:10.1016/j.virol.2006.12.019Karlsson et al., 2001, 2004; Perron et al., 1997b). MSRV
(Komurian-Pradel et al., 1999; Perron et al., 1989, 1997a) is
presumably a complete virus since it is able to form extracellular
virions that are found in the blood of MS patients and whose
presence in the cerebrospinal fluid (CSF) of MS patients
strongly correlates with disease outcome (Dolei et al., 2002;
Sotgiu et al., 2002a, 2002b, 2006). Syncytin-1 is the env gene of
ERVWE1, a replication-incompetent HERV-W member,
located on chromosome 7q21–22 (Blaise et al., 2003; Blond
et al., 1999; Dolei, 2006; Tristem, 2000), in a candidate region
for genetic susceptibility to multiple sclerosis (Wei et al., 1995).
Syncytin-1 can be considered as a specific marker of the human
trophoblast (Malassine et al., 2005). It is expressed in human
placenta during early pregnancy, and found to be responsible for
fusion of fetal trophoblast cells into the placental multinucleated
syncytiotrophoblast layer, hence allowing embryo implantation
(Mi et al., 2000; Muir et al., 2004). Moreover, it has been
121G. Mameli et al. / Virology 362 (2007) 120–130hypothesized that HERVenv expression in pregnancy may play
a role in suppressing the maternal immune response against the
fetal allograft (Villarreal, 1997). In the trophoblast, syncytin-1
expression was found to be regulated by a bipartite element
consisting of a cyclic AMP (cAMP)-inducible long terminal
repeat (LTR) retroviral promoter adjacent to a cellular enhancer
known as the trophoblast-specific enhancer (TSE) which
confers a high level of expression and placental tropism
(Prudhomme et al., 2004). The activity of this promoter was
found to be regulated by several transcription factors, including
AP-2, Sp-1, and GCMa (Prudhomme et al., 2004).
Syncytin-1 is highly related to MSRV env (Dolei, 2005).
Until now, no specific primers have been identified to
discriminate sequences of extracellular MSRV from those
possibly transcribed from endogenous HERV-W DNAs, such
as the ERVWE1 locus (syncytin-1). Similarly, no antibody has
been identified so far that is specific for an epitope unique to a
virion-producing/pathogenic MSRV/HERV-W strain that does
not label any protein encoded by any of the normally expressed
endogenous HERV-W DNA copies (Perron et al., 2005).
Different groups have found that the levels of HERV-W env-
specific mRNA and/or protein (syncytin-1 and/or MSRV) were
significantly higher in MS brains than in controls (Antony et al.,
2004; Mameli et al., 2007). This is related to active
demyelination and inflammation and has been proposed to be
responsible for at least some pathogenic phenomena of MS
(Antony et al., 2004; Johnston et al., 2001; Mameli et al., 2007).
Expression patterns for HERV-W gag and env proteins have
been detected in MS lesions that are “MS-specific” essentially at
the level of endothelial and microglial cells (Perron et al., 2005).
Up-regulation of syncytin-1/HERV-W/MSRV-env immuno-
reactivity was observed in MS lesions within plaques and this
is related to the extent of active demyelination and inflammation
(Antony et al., 2004; Mameli et al., 2007). Immunostaining was
also detected in astrocytes and microglia cells (Antony et al.,
2004; Blond et al., 2000; Mameli et al., 2007; Perron et al.,
2005).
No data are available so far on the mechanisms of syncytin-1
regulation in nerve tissue; it is known that different cell types
can have cell-specific transcription factors (Sawaya and
Schaeffer, 1995). Therefore, we evaluated the molecular
mechanisms involved in the regulation of the syncytin-1
promoter by MS-related cytokines in human astrocytic cells.
Result
HW/promoter sequences
Compared to healthy individuals, patients with MS have
significant variations in HERV-W/MSRV/syncytin-1 expres-
sion, both at the RNA and protein level in astrocytic cells
(Antony et al., 2004; Mameli et al., 2007; Perron et al., 2005).
This could be either intrinsic to the promoter or due to
differential activation by environmental (inflammatory) stimuli.
To clarify this issue, we analyzed the sequence of the syncytin-1
promoter present in the DNA of patients and controls. To this
end, DNAwas isolated from the PBMC of 8 MS patients and 2control individuals. The DNAwas then amplified by PCR using
primers against the complete promoter region (cellular+viral
LTR moieties, −436/+310) as described in Materials and
methods. The amplified products were sequenced in both
directions and compared to the URE-LTR region present in
GenBank (NM-014590). Data are not shown for the sake of
brevity, but all the sequences belong unequivocally to the
ERVWE1 locus of the HERV-W family. Notably, this DNA
region was found to be extremely stable since we observed only
one point mutation in one of the 8 experimental sequences, with
respect to the entire 633 nucleotide URE-LTR region present in
GenBank.
Cytokine regulation of URE-LTR promoter activity
Since the URE-LTR sequence of patients and controls is
almost identical, this provided us with a rationale to see whether
the syncytin-1 promoter can be regulated by cytokines relevant
in MS. We constructed three HW/promoter-Luc reporter
plasmids containing the various regions of the syncytin-1
upstream regulatory sequence (URE-LTR: −436/+310; TSE-
LTR: −67/+310; LTR: +1/+310) fused to the luciferase reporter
gene. A schematic representation of the three regions is shown
in Fig. 1A. Human U-87MG astroglioma cells were transfected
with one of the above HW/promoter-Luc reporter plasmids.
Twenty-four hours after transfection, the cells were treated with
MS-detrimental cytokines (TNFα, IL-1β, IL-6, and IFNγ) or
the MS-beneficial cytokine, IFNβ. As shown in Fig. 1B, the full
length syncytin-1 promoter is activated by the MS-detrimental
cytokines, while IFNβ is inhibitory (80% reduction of
luciferase activity). Among the MS-detrimental cytokines, IL-
1β, IL-6, and IFNγ modestly activate the full length promoter
(1.8-, 2.1-, and 2.9-fold increase, respectively), while TNFα
activates the syncytin-1 promoter by 5.7-fold. The effect on the
promoter activity is dose-dependent, as reported on Figs. 2A–B
for TNFα and IFNβ; for both cytokines, the effective doses
are around 100–1000 pg/ml, even though TNFα and IFNβ
exert opposite effects on the URE-LTR promoter. When the
−436/−66 domain is deleted (i.e. the −436/−128 positive
regulatory region and the −128/−66 negative LTR regulatory
region), but the TSE domain, that is crucial for trophoblast
expression (Prudhomme et al., 2004), is present, the activity of
TNFα, IFNγ, and IFNβ is reduced, but not that of IL-1 and IL-6
(Fig. 1C). As shown in Fig. 1D, all the MS-detrimental
cytokines were able to enhance (by ∼2.0-fold over the basal
activity) the minimum DNA sequence spanning between −1 to
+310 of the syncytin-1 promoter, i.e. the viral LTR moiety.
Surprisingly, the deletion of the cellular moiety of the promoter
changed the effect of IFNβ from inhibitory to stimulatory to
an extent similar to that of the MS-detrimental cytokines
(∼2.0-fold).
Syncytin-1 regulation by NF- κB and APD transcription
factors
Next, we used a program that predicts putative transcription
factor binding sites to examine the DNA sequence of the
Fig. 1. Regulation of the syncytin promoter byMS-detrimental or MS-beneficial cytokines in U-87MG astroglioma cells transfected with full length or deletion mutant
HW/promoter-Luc reporter plasmids. (A) Schematic representation of the three HW/promoter-Luc reporter plasmids, containing the various regions of the syncytin
promoter fused to the luciferase reporter gene: the cellular upstream regulatory sequence (URE) is reported in black, and the viral LTR is reported in grey. (B) Cytokine
regulation of luciferase activity in U-87MG astrocytes transfected with the full length (URE-LTR: −436/+310). Twenty-four hours after transfection, the cells were
treated overnight with 1 ng/ml of MS-detrimental (IL-1β, TNFα, IFNγ, and IL-6) or MS-beneficial (IFNβ) cytokines. (C) Luciferase activity of astrocytes transfected
with the TSE-LTR: −67/+310, where the −436/−128 positive regulatory region and the −128/−66 negative LTR regulatory region of the cellular moiety of the
promoter have been deleted, but it is present in the TSE domain, that is crucial for syncytin expression in trophoblasts. (D) Luciferase activity of astrocytes transfected
with the LTR: +1/+310, where only the viral moiety of the promoter is present. Data are the mean of three experiments, run in duplicate, and are expressed as fold
activation of luciferase activity by cytokines over the control values, taken as one.
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found to be crucial for the activity of TNFα, IFNγ and IFNβ.
This sequence was found to contain putative κB and AP-1-
binding motifs, that are probable binding sites for NF-κB and
AP-1 transcription factors (not shown). Therefore we evaluated
the effects of the above transcription factors on the regulation of
the syncytin-1 promoter. Since it has been shown that addition
of PMA leads to the induction of NF-κB and AP-1 transcription
factors (Shin et al., 2005), we tested the effects of PMA on the
promoter activity. We found that PMA did indeed activate the
syncytin-1 promoter in U-87MG cells. The maximum effect of
>1 Log was found when cells were exposed to 10–100 pg/ml of
PMA (Fig. 2C).
To test the binding of NF-κB and AP-1, new (−436/+310)
reporter plasmids were created, in which the κB and AP-1binding sites were deleted, as described in Materials and
methods. A schematic representation of the deletion mutants
is shown in Fig. 3A. U-87MG cells were transfected with
URE-LTR-Luc (−436/+310) or its deletion mutants, Δ-κB
URE-LTR-Luc, and AP-1 URE-LTR-Luc reporter plasmids.
Twenty-four hours post-transfection, the cultures were treated
overnight with PMA or cytokines. Cell extracts were
prepared, and luciferase assays were then performed. As
shown in Fig. 3B, deletion of the κB and AP-1-binding sites
did not affect significantly the basal promoter activity. On the
other hand, in cytokine treated cells, the deletion of both
binding sites resulted in a reduction of the effects of the
cytokine on luciferase activity, both of stimulation (IL-1β,
TNFα, IFNγ, and IL-6) and of inhibition (IFNβ). Of note, the
effect of PMA was almost completely abolished, thus
Fig. 2. Luciferase activity of URE-LTR: −436/+310 in U-87MG astrocytes
treated with different concentrations of TNFα (A) and PMA (B) and IFNβ (C).
See legend to Fig. 1 for details. Data are the mean of two experiments, run in
duplicate, and are expressed as fold activation of luciferase activity by cytokines
over the control values, taken as one.
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mediated by the induction of NF-κB and AP-1 transcription
factors.Role of the NF-κB p65 subunit
NF-κB is normally sequestered in the cytoplasm as a p65/
p50 heterodimer or a p50/p50 homodimer of proteins of the
Rel family of transcription factors (Narayanan et al., 1993).
The ability of PMA and/or TNFα to induce its translocation
as a p65/p50 heterodimer to the nucleus (thus rendering it
transcriptionally active), led us to perform experiments in the
absence of NF-κB, using interfering RNA against p65
(siRNA-p65). First we examined the ability and efficiency
of siRNA-p65 to silence the gene of the p65 NF-κB subunit.
U-87MG cells were transfected with 400 nM of siRNA-p65.
As a positive control, parallel cultures were also treated with
TNFα, which has the capability to induce NF-κB. Twenty-
four hours later, the cultures were collected, washed, and
lysed. Total protein extracts were prepared and processed for
Western blot analysis. As shown in Fig. 4A, p65 was
completely silenced in extracts prepared from siRNA-p65-
transfected cells, that were untreated or received TNFα
stimulation (compare lanes 1 and 3 to lanes 2 and 4,
respectively). To investigate the functional relevance of p65-
DNA interactions, we studied effects of p65 on URE-LTR
promoter activation in U-87MG cells in the presence and
absence of siRNA-p65. Twenty-four hours after transfection
of siRNA-p65 and reporter plasmids, the cells were exposed
to cytokines for additional 24 h, then collected and processed
for luciferase assay. As shown in Fig. 4B, when the NF-κB
p65 is silenced, the URE-LTR promoter activation by TNFα
and IFNγ, as well as its inhibition by IFNβ was abolished.
Therefore, we conclude that the presence of NF-κB p65 is
necessary for the regulation of the ERVWE1 promoter by
TNFα, IFNγ and IFNβ.
Binding of NF-κB p65/p50 heterodimer to a κB site within the
ERVWE1 promoter
The data from the experiments with the deletion mutants and
the p65 siRNA strongly suggested that NF-κB sites are crucial
for regulation of syncytin-1 expression by TNFα, IFNγ, and
IFNβ, as well as by PMA. Therefore, we examined whether
TNF and PMA affect the p65 subunit of NF-κB, by enhancing
its binding to its DNA cognate motif within the syncytin-1
promoter.
To demonstrate the binding of the p65/p50 heterodimer to
the NF-κB binding site within the URE-LTR syncytin-1
promoter, a gel electrophoretic mobility shift assay (EMSA)
was performed with 10 μg of nuclear extracts from either
untreated or TNFα-treated cells. Nuclear extracts were
incubated with a 32P-labeled ERVWE1 κB oligonucleotide
probe or with a κB consensus probe, as a control. Data of a
representative EMSA gel experiment are shown in Fig. 5A.
Arrows indicate that the relevant bands are detected also with
the ERVWE1 κB probe. As shown in Fig. 5B, a Western blot
assay, performed utilizing anti-p65 antibody, shows a rapid
increase of the intensity of the band corresponding to the
DNA–p65 complex from U-87MG cells exposed to 1 ng/ml
of TNFα or 10 pg/ml of PMA relative to untreated cells. An
Fig. 3. Regulation of the syncytin promoter by NF-κB and APD transcription factors. (A) Schematic representation of the deletions: full length URE-LTR-Luc reporter
plasmid, Δ-κB and ΔAP-1 URE-LTR: −436/+310. The cellular URE is reported in black, and the viral LTR is reported in grey. (B) Luciferase activity of U-87MG
astrocytes transfected with full length URE-LTR: −436/+310 (black bars), or Δ-κB URE-LTR (light grey bars) and ΔAP-1 URE-LTR (dark grey bars) plasmids.
Cultures were treated with 1 ng/ml of cytokine or 10 pg/ml of PMA. Experimental details as in Fig. 1.
Fig. 4. Silencing of the NF-κB p65 subunit and regulation by cytokines of syncytin promoter. (A)Western blot assay of protein extracts from U-87MG cells transfected
with 400 nM of siRNA-p65 and left overnight with/without 1 ng/ml of TNFα. The relevant bands were recognized by anti-p65 antibody. The anti-Grb2 antibody was
used to control that equal amounts of proteins were loaded. (B) Relative luciferase activity of URE-LTR-Luc reporter plasmid in cytokine-treated U-87MG astrocytes
as such (black bars) and in the presence of siRNA-p65 (grey bars).
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Fig. 5. Binding of NF-κB to a κB site within the HW/promoter. (A) Gel elecrophoretic mobility shift assay (EMSA) of NF-κB p65/P50 binding to the B binding site
within the URE-LTR promoter. Ten micrograms of nuclear extracts from either untreated or TNFα-treated cells, challenged with a 32P-labeled URE-LTR B (−204/
−214) oligonucleotide probe, or with a B consensus probe, as a control. The arrowheads indicate the NF-κB p65/P50 and p50/50 bands and the free probes. (B)
Western blot assay of protein extracts from U-87MG cells treated for different times with 1 ng/ml of TNFα or 10 pg/ml of PMA. The anti-p65 antibody reveals a
prompt increase of the intensity of the band corresponding to the DNA–p65 complex from U-87MG cells exposed to TNFα or PMA, with respect to untreated cells.
The anti-Grb2 antibody was used to control that equal amounts of proteins were loaded. (C) Chromatin immunoprecipitation (ChIP) analysis of NF-κB binding to the
κB site within the ERVWE1 promoter in U-87MG cells transfected with the URE-LTR-Luc plasmid and treated with 1 ng/ml of TNFα or PMA for different times. See
Materials and methods for details. The chromatin-bound endogenous p65 induced by TNFα or PMAwas recognized by the anti-p65 antibody. (D) ChIP assay of NF-
κB binding to the κB site within the ERVWE1 promoter, as recognized by anti-p65 and anti-p50 antibodies, but not by unrelated antibody (serum): NF-κB binding is
abolished when the U-87MG cells (both as such or treated with 1 ng/ml of TNFα, as a further positive control) are transfected also with siRNA-p65. See text for details.
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24 h, particularly in the PMA-treated cultures, while that of
the Grb2 housekeeping gene was almost unaffected. In order
to verify the p65 specificity of the interaction with the κB site
within the syncytin-1 promoter, U-87MG cells were treated
with TNFα or PMA for different times. The cultures were
then harvested and processed for ChIP assay using anti-p65
antibody as described in Materials and methods. As shown in
Fig. 5C, the anti-p65 antibody recognized the chromatin-
bound endogenous p65 induced by TNFα or PMA. In
agreement with the data of Fig. 5B, maximal p65 induction
by TNFα required 1 h of exposure (lane 3). The interplay
between κB URE-LTR and p65/p50 was further studied in the
absence of p65 using siRNA-p65. U-87MG cells were
transfected or not with siRNA-p65. Parallel cultures were
also treated with TNFα, as a positive control. Forty-eight
hours after transfection, the cells were harvested andprocessed for ChIP assay using antibodies directed against
p65 or p50 proteins. As shown in Fig. 5D, endogenous as
well as TNFα-induced p50 or p65 binds to URE-LTR DNA
(lanes 2 and 6). No interaction was observed when the
siRNA-p65 was present (lanes 1 and 5), and when the non-
specific serum was used (lanes 3 and 7). We conclude that the
binding of the p65/p50 heterodimer to the κB site within the
URE-LTR syncytin-1 promoter is likely to be crucial for
syncytin-1 induction by TNFα.
Discussion
In addition to the recognized physiological role of syncytin-1
in trophoblast fusion during pregnancy, HERV-W components
are expressed in a variety of conditions, recently reviewed by
Dolei (2006). There is much experimental evidence linking the
HERV-W family to MS and multiple parallels exist between the
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presence and outcome of MS (Dolei, 2005). Two members of
the HERV-W family are known to possess a complete env ORF:
MSRV and syncytin-1. The former (Komurian-Pradel et al.,
1999; Perron et al., 1989, 1997b) is a presumably complete
virus, releasing free virions, whose presence in the CSF strongly
correlates with MS progression and outcome (Dolei et al., 2002;
Sotgiu et al., 2002b, 2006). Syncytin-1 is the env gene product
of the replication-incompetent ERVWE1, located on chromo-
some 7q21–22 (Blaise et al., 2003; Blond et al., 2000; Dolei,
2006; Tristem, 2000), in a candidate region for genetic
susceptibility to multiple sclerosis (Wei et al., 1995). Several
studies, including ours, have shown that HERV-Wexpression is
increased in MS patients (Dolei et al., 2002; Garson et al., 1998;
Johnston et al., 2001; Mameli et al., 2007; Nowak et al., 2003;
Perron et al., 1997b). Pro-inflammatory properties of syncytin-1
and MSRV on the nervous system in MS are strikingly
concordant, and strengthen the possibility of a role in human
disease for HERV-W, which may be a target for therapeutic
intervention (Antony et al., 2004; Dolei, 2005; Garson et al.,
2005). The MSRV can be recognized, when it is detected as free
virions in the blood and CSF (Dolei et al., 2002; Garson et al.,
1998; Serra et al., 2003), and its link to MS is apparent, even
though it is not proven if it is a cause or a consequence of the
disease (Dolei, 2005, 2006; Garson et al., 2005). Syncytin-1 can
be found only cell-associated, since ERVWE1 is replication-
incompetent. Consequently, at the intracellular level, in the
absence of specific antibody or primers that could discriminate
the various HERV-Ws, MSRV, HERV-W, and syncytin-1, they
cannot be differentiated from each other (Perron et al., 2005).
Therefore there is a debate (Dolei, 2005; Garson et al., 2005)
about which HERV-W is activated in MS, since both have been
shown to possess immunopathogenic features in vitro and in
vivo (Antony et al., 2004; Brudek et al., 2004; Firouzi et al.,
2003; Lafon et al., 2002; Menard et al., 1997; Perron et al.,
1997a, 2001).
To clarify this issue, we have now performed a study of the
syncytin-1 promoter, to give insight into the possible mechan-
ism(s) that regulate the expression of syncytin-1. This was
carried out in U-87MG astrocytic cells, since various lines of
evidence strongly suggest that the astrocyte is a key cell in MS,
that facilitates recruitment and retention of pro-inflammatory
leukocytes in the CNS. These events are a prologue to the
neuropathology (Moynagh, 2005) and also occur in MS
neuroinflammation, leading to the formation of demyelinated
lesions. In a previous study (Mameli et al., 2007), we analyzed
brain sections by immunostaining with HERV-W env-specific
antibody. We found that the MSRV/HERV-W-env protein was
clearly detected only in samples from patients with MS.
Immunostaining was found within MS lesions, and its intensity
correlated with active demyelination and inflammation. In
chronic-active MS plaques, ∼50% of total glial cells were
immunoreactive and thus contained the env protein. The
MSRV/HERV-W/syncytin-1 signal was mostly localized
observed on cells morphologically resembling both microglia
and hypertrophic astrocytes. The same study excluded MS-
specific presence and expression of the human herpesvirus 6,both in brain and in blood cells. These findings are in keeping
with studies of MS brains (Antony et al., 2004; Mameli et al.,
2007; Perron et al., 2005), showing absolute or relative
accumulation of HERV-W env RNA and protein in brain from
MS patients, in astrocytes and microglia.
In the present study, we analyzed firstly the sequence of the
syncytin-1 promoter; alignment of the URE-LTR region of MS
patients and controls to the human syncytin-1 sequence
(NM_014590) revealed an almost complete identity (only one
point mutation in one of the nine 633 nt sequences). This
excluded the possibility that the increased expression in MS was
due to genetic differences in the ERVWE1 promoter. For this
reason, we hypothesized that the increase could be attributable
to the inflammatory microenvironment. This is also in
accordance with the observation of a positive back loop on
MSRV expression and release (Serra et al., 2003) that can be
generated in human lymphocytes by pro-inflammatory cyto-
kines such as those triggered by MSRVenvelope itself (Rolland
et al., 2005).
The regulation of ERVWE1 in trophoblast cells has been
studied; the syncytin-1 promoter was found to contain potential
binding sites for the following nuclear transcription factors:
CBF (CCAAT binding factor), Oct-1 (octamer protein), Ap-1,
and Sp-1. Oct-1 and CBP are critical for transcriptional
regulation of the gene in this cell type (Cheng et al., 2004; Mi
et al., 2000; Prudhomme et al., 2004). In the cellular enhancer
URE region adjacent to the ERVWE1-5′LTR, Prudhomme et al.
(2004) described a positive regulatory region from position
−436 to −128, a LTR retrotransposon negative regulatory
region from position −128 to −67, a trophoblast-specific
enhancer (TSE) from position −67 to −35, and putative AP-2,
Sp-1, and GCMa binding sites as essential constituents of the
33-bp TSE.
These data, and the question of which factors can induce
syncytin-1 (over) expression, have prompted us to search for
correlations between pro-inflammatory cytokines and ERVWE1
promoter regulation in astrocytic cells. We focused on the cellular
moiety of the promoter, to look for possible astrocyte-specific
domains, by means of transient transfection of U-87MG cells
with HW/promoter-Luc reporter plasmids. These plasmids
contain the whole region of the syncytin-1 upstream regulatory
sequence that has been fused to a luciferase reporter gene, or
selected deletion mutants.
Our data show for the first time that the syncytin-1 promoter
is activated by proinflammatory cytokines that are known to be
detrimental for the outcome of MS, while it is inhibited by the
MS-beneficial cytokine, IFNβ. These findings parallel the
response of MSRV to the same cytokines in vivo (Serra et al.,
2003). This indicates that both HERV-W members can be
activated in an inflammatory environment. By astrocyte
transfection with deletion mutants of this enhancer domain,
we next showed that the URE plays a role in promoter
regulation by MS-related cytokines in U-87MG cells. The
region of the promoter spanning from −436 to −67 is important
for the full activation by TNFα, IFNγ and IFNβ, but not for that
of IL-1β and IL-6. In our experimental conditions, the highest
activity was detected in cells treated with TNFα (6-fold) and
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al. (2004), of increased syncytin-1 expression in PMA-treated
U-373 astrocytes. Of note, if only the viral moiety of the
promoter is left, an overall doubling of expression is observed
upon treatment with all of the cytokines used. This finding
suggests that (i) the cellular enhancer is irrelevant for syncytin-1
activation by IL-1β and IL-6; (ii) the LTR moiety of the
promoter is responsible for the ∼2-fold activation by all the
cytokine tested, including IFNβ; (iii) the response to the latter
cytokine is dual, with a dominant inhibitory action, due to the
cellular −436/−67 domain, and a stimulatory one, linked to the
viral moiety of the syncytin-1 promoter.
We found that the DNA sequence of the syncytin-1 promoter
spanning between −436 to −1 was crucial for the activity of
TNFα, IFNγ, and IFNβ. By computer analysis, of this region,
we identified two putative binding sites for the NF-κB and AP-1
transcription factors. These could be important for the promoter
regulation by the above cytokines. When U-87MG astrocytes
were transfected by Δ-κB or ΔAP-1 URE-LTR mutants, there
was a reduction of the effects of cytokines both of stimulation
(IL-1β, TNFα, IFNγ, and IL-6) and of inhibition (IFNβ). Also
the effect of PMA was abolished, indicating that the PMA
activation of syncytin-1 expression is mediated by the induction
of NF-κB and AP-1 transcription factors.
This finding led us to perform experiments of syncytin-1
regulation in the absence of NF-κB, using siRNA-p65, that
silenced the effects of TNFα, IFNγ and IFNβ, but not of IL-1β
and IL-6, thus indicating that NF-κB is involved only in the
syncytin-1 regulation by the former cytokines.
In our hands, the highest activation of the syncytin-1
promoter was achieved by treatment of U-87MG astrocytes
with PMA or TNFα and these compounds are known to induce
NF-κB translocation as a p65/p50 heterodimer to the nucleus
where it is transcriptionally active (Beg and Baltimore, 1996).
This occurred also in U-87MG cells, where as few as 15 min of
treatment was sufficient for the formation of the DNA–p65
complex. The physical interaction of the p65/p50 NF-κB
heterodimer with the cis element present in the URE-LTR
syncytin-1 promoter was proven in vitro, by EMSA with
nuclear extracts from either untreated or TNF-treated cells,
incubated with a ERVWE1 κB probe or with a κB consensus
control probe. The interaction has been shown to occur also in
vivo, as detected in lysates from astrocytes transfected with
URE-LTR in the presence of TNFα or PMA by ChIP assay,
using antibody against p65 or p50 subunits. In addition, this
interplay between p65/p50 and κB URE-LTR was completely
abolished in the presence of siRNA-p65. These in vitro and in
vivo data indicate that the binding of the p65/p50 heterodimer to
the κB site within the URE-LTR syncytin-1 promoter is likely to
be a crucial event for syncytin-1 induction by TNFα and PMA.
In conclusion, we have shown that, in the astrocyte, a cell
type that is crucial for MS neuropathology, the syncytin-1
promoter can be activated by the same cytokines that are known
to contribute to MS onset and outcome. Though TNFα is
generally considered detrimental for MS, emerging data suggest
that in certain disease stages it might also have positive
influence, as reviewed by Martino et al. (2002). This could berelated to TNFα signaling through two separate receptors,
resulting proinflammatory the one through TNFR1, and
protective through TNFR2 (i.e. induction of the proliferation
of oligodendrocyte progenitors).
Furthermore the promoter is inhibited by IFNβ, a cytokine
that is used for MS therapy exactly as it occurs for MSRV
(Serra et al., 2003), the other HERV-W member. Therefore,
both HERV-W members are likely to be activated in vivo,
during MS. The data also indicate that the URE, the cellular
upstream regulatory moiety of the promoter, plays an
important role in the regulation of syncytin-1 in U-87MG
cells. In particular, we identified two putative binding sites for
NF-κB and AP-1 factors, which are important for the
stimulation by TNFα, IFNγ, and PMA, and essential for the
inhibition by IFNβ. Lastly, the physical interaction between
the NF-κB p65 and p50 subunits and the κB site within the
promoter has been shown to occur, both in vivo, in the
astrocyte, and in cell-free extracts.
Materials and methods
HW/promoter sequence
Amplified products were obtained by PCR utilizing primers
specific for the entire URE-LTR region (−436/310); HW(−436)
5′-aaggtacctatgtattaccataattaggcagc-3′; HW (+310) 5′-aaagatc-
taatagagtgaaatagcatgaaaacagc-3′ (Prudhomme et al., 2004).
PCR products were then sequenced in both directions with
the Fluorescent Big Dye System (Perkin Elmer Abi PRISM 310
Genetic Analyzer, Emeryville, CA). Sequence analysis was
carried out using CLUSTAL-X (Thompson et al., 1997) for
multiple sequence alignment and putative transcription factor
binding sites were identified by computer analysis with the
Transcription Element Search System of the University of
Pennsylvania (http://cbil.upenn.edu/tess/index.html).
Plasmid pGL3-LTR construction
To create the three HW/promoter-Luc reporter plasmids
(URE-LTR: −436/+310; TSE-LTR: −67/+310; LTR-LTR: +1/
+310), the promoter regions were amplified from genomic
DNA isolated from U-87MG astrocytic glial cells. The resulting
PCR products were subcloned into the KpnI/BglII sites of the
pGL3 luciferase reporter plasmid (Promega, Madison, WI). The
sequences of the oligonucleotides (Prudhomme et al., 2004)
used in PCR were as follows:
(a) (URE-HW −436) up 5′-aaggtacctatgtattaccataattagg-
cagc-3′
(b) (TSE-HW −67) up 5′-ggacagtgaacatagacggtaccccct-
ggggcgggcttcc-3′
(c) (LTR-HW +1) up 5′-ttggtacctgagagacaggactagct-3′
(d) (LTR-HW +310) down 5′-aaagatctaatagagtgaaatagcat-
gaaaacagc-3′
As for the deletion mutants, the Δ-κB URE-LTR-Luc repor-
ter and the ΔAP-1 URE-LTR-Luc reporter plasmids were
128 G. Mameli et al. / Virology 362 (2007) 120–130generated by in vitro PCR-directed mutagenesis using the Quik-
Change site-directed mutagenesis kit as recommended by the
manufacturer (Stratagene, La Jolla, CA). The oligonucleotides
used for deletion mutagenesis were the following:
Δ-κB (coding) 5′-cgacgttgtggtatatcctaattcaacatccattccaac-3′
Δ-κB (non coding) 5′-gttggaatggatgttgaattaggatatacca-
caacgtcg-3′
ΔAP-1 (coding) 5′-ggagagtgaacatgatcttc-3′
ΔAP-1 (non coding) 5′-gaagatcatgttcactctcc-3′
Cell culture, transfection, and luciferase assays
The human astrocytic glial cell line U-87MG was maintained
in Dulbecco's modified Eagle's medium supplemented with
10% fetal calf serum (Life Technologies, Inc., CA). The cells
were transfected using the Fugene 6 (Roche Ltd., Basel,
Switzerland) method, with 1 μg of the reporter plasmids (URE-
LTR-Luc, TSE-LTR-Luc, LTR-Luc, see below). To control the
concentration of the promoter DNA sequence in transfection,
empty pcDNA3 plasmid was added to the transfection mixture.
Each transfection was repeated a minimum of three separate
times with at least three different plasmid preparations. Twenty-
four hours post-transfection, the human recombinant cytokines
(IFNγ, IFNβ, IL-1, and TNFα, all purchased from Sigma-
Aldrich, St. Louis, MO, and IL-6, Roche) and phorbol-12-
myristate-13-acetate (PMA) were added, at doses of 1 ng/ml for
the cytokines and 10 pg/ml for PMA. Cell extracts were
prepared 48 h after transfection and luciferase assays were
performed according to the manufacturer's instructions (Pro-
mega, Madison, WI).
Western blot analysis and antibodies
Western blotting was performed on total cell lysates (50 μg/
sample) as described previously (Sawaya et al., 1998).
Antibodies against p65 NF-κB subunit, and the growth factor
receptor-binding protein 2 (Grb2), housekeeping protein, used
to control that equal amounts of protein were loaded, were used
to detect the level of these proteins (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA).
RNA interference
Transient knockdown of p65 was performed with p65-
specific siRNA: 5′-GCCCUAUCCCUUUACGUCAdTdT
(Dharmacon Research, Inc., Lafayette, CO). After 24 h of
plating, cells were rinsed once with Optimem (Invitrogen,
Carlsbad, CA). siRNA was transfected/added at a final
concentration of 400 nm by the method of Surabhi and Gaynor
(2002) into U-87MG cells in serum free Optimem (Invitrogen,
Carlsbad, CA) alone or in the presence of 1 μg of HW/
promoter-Luc reporter plasmid, by using lipofectamine trans-
fection reagents (Invitrogen). Western blot analysis of protein
extracts from untransfected cells or cells transfected with p65-
specific siRNA using anti-p65 was performed. For loading
controls, anti-Grb2 antibody was used.Electromobility shift assay (EMSA)
EMSA was performed as described previously (Amini et
al., 2002). Nuclear extracts were prepared from U-87MG
cells, either untreated or treated with TNFα. The oligonucleo-
tide probes, corresponding to the κB binding site within a
URE-LTR promoter region were κB up 5′-tagatgaattcattc-3′
and κB down 5′-gaatgaattcatcta-3′, and κB consensus
oligonucleotide was 5′-gttgagggactttc-3 (MWG Biotech).
The probes were annealed, labeled with [γ-32P] ATP and
incubated at 4 °C for 20 min with 10 μg of nuclear extracts.
Each mixture was then fractionated on non-denaturing TBE
gels. After electrophoresis, the gel was dried and exposed to
X-ray film at −70 °C.
ChIP assay
U-87MG astrocytes were grown overnight in 100-mm
dishes to reach 60 to 70% confluence. The cultures were then
treated with medium alone, TNFα (1 ng/ml) or PMA (10 pg/
ml) and returned to the incubator for 15′, 39′, 69′, and 24 h.
Cells were cross-linked with formaldehyde, harvested, and
chromatin immunoprecipitation (IP) (ChIP) was performed
using 5×106 cells per immunoprecipitation reaction. The
remainder of the procedure followed standard protocols for
ChIP analysis, as previously described (Amini et al., 2005;
Wells and Farnham, 2002). The resulting DNA was analyzed
by PCR, using the following URE-LTR primers: 5′-aactgcct-
gacctctgccacccc-3′ (up) (−320) 5′-agttgaagatcatgtgactcagtaa-3′
(down) (−122). Antibody used in the ChIP procedure was
against p65 and p50, as well as rabbit anti-mouse immunoglo-
bulin G (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) as a
negative control.
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